{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T23:37:36Z","timestamp":1794872256444,"version":"4.9.1"},"reference-count":31,"publisher":"American Society of Hematology","issue":"18","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,24]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Exosomes have emerged as promising vehicles for delivering therapeutic cargoes to specific cells or tissues, owing to their superior biocompatibility, reduced immunogenicity, and enhanced targeting capabilities compared with conventional drug delivery systems. In this study, we developed a delivery platform using exosomes derived from monocytes, specifically designed for targeted delivery of bortezomib (Btz) to multiple myeloma (MM) cells. Our approach involved the genetic modification of monocytes to express antibodies targeting B-cell maturation antigen (anti-BCMA), because BCMA selectively expresses on myeloma cells. This modified anti-BCMA was then efficiently incorporated into the monocyte-derived exosomes. These adapted exosomes effectively encapsulated Btz, leading to enhanced drug accessibility within MM cells and sustained intracellular accumulation over an extended period. Remarkably, our results demonstrated that anti-BCMA\u2013modified exosome-loaded Btz (anti-BCMA-Exo-Btz) outperformed free Btz in\u00a0vitro, exhibiting a more potent myeloma-suppressive effect. In orthotopic MM xenograft models, anti-BCMA-Exo-Btz exhibited a significant antitumor effect compared with free Btz. Furthermore, it demonstrated remarkable specificity in targeting Btz to myeloma cells in\u00a0vivo. Importantly, we observed no significant histological damage in mice treated with anti-BCMA-Exo-Btz and a slight effect on peripheral blood mononuclear cells. In addition, our study highlighted the multifunctional potential of monocyte exosomes, which induced cell apoptosis, mediated immune responses, and enhanced the osteogenic potential of mesenchymal stromal cells. In conclusion, our study suggests that exosomes modified with targeting ligands hold therapeutic promise for delivering Btz to myelomas, offering substantial potential for clinical applications.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012464","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T18:47:44Z","timestamp":1718390864000},"page":"4886-4899","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Anti-BCMA\u2013engineered exosomes for bortezomib-targeted delivery in multiple myeloma"],"prefix":"10.1182","volume":"8","author":[{"given":"Shushu","family":"Yuan","sequence":"first","affiliation":[{"name":"1Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, China"},{"name":"2Department of Cell Biology, School of Biology & Basic Medical Sciences, Suzhou Medical College of Soochow University, Suzhou, China"},{"name":"3Department of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5249-0070","authenticated-orcid":false,"given":"Chuan","family":"He","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengli","family":"Bing","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyun","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Wang","sequence":"additional","affiliation":[{"name":"2Department of Cell Biology, School of Biology & Basic Medical Sciences, Suzhou Medical College of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifang","family":"Zhao","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Chai","sequence":"additional","affiliation":[{"name":"2Department of Cell Biology, School of Biology & Basic Medical Sciences, Suzhou Medical College of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingzong","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8552-991X","authenticated-orcid":false,"given":"Wenzhuo","family":"Zhuang","sequence":"additional","affiliation":[{"name":"2Department of Cell Biology, School of Biology & Basic Medical Sciences, Suzhou Medical College of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"issue":"5","key":"2024092412010353400_bib1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"2024092412010353400_bib2","first-page":"CD010816","article-title":"Bortezomib for the treatment of multiple myeloma","volume":"4","author":"Scott","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2024092412010353400_bib3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1083\/jcb.201210077","article-title":"Development of proteasome inhibitors as research tools and cancer drugs","volume":"199","author":"Goldberg","year":"2012","journal-title":"J\u00a0Cell Biol"},{"issue":"1","key":"2024092412010353400_bib4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/biom12010051","article-title":"Progress on the application of bortezomib and bortezomib-based nanoformulations","volume":"12","author":"Liu","year":"2021","journal-title":"Biomolecules"},{"issue":"12","key":"2024092412010353400_bib5","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2015.66.0662","article-title":"Case example of dose optimization using data from bortezomib dose-finding clinical trials","volume":"34","author":"Lee","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024092412010353400_bib6","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.7150\/thno.52570","article-title":"Engineering exosomes for targeted drug delivery","volume":"11","author":"Liang","year":"2021","journal-title":"Theranostics"},{"issue":"1-2","key":"2024092412010353400_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11010-019-03545-4","article-title":"Exosomes: cell-created drug delivery systems","volume":"459","author":"Familtseva","year":"2019","journal-title":"Mol Cell Biochem"},{"issue":"Pt A","key":"2024092412010353400_bib8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.addr.2016.02.006","article-title":"Extracellular vesicles for drug delivery","volume":"106","author":"Vader","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"2024092412010353400_bib9","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.2147\/IJN.S388604","article-title":"Exosomes derived from immune cells: the new role of tumor immune microenvironment and tumor therapy","volume":"17","author":"Wang","year":"2022","journal-title":"Int J Nanomed"},{"key":"2024092412010353400_bib10","doi-asserted-by":"crossref","first-page":"553576","DOI":"10.3389\/fcell.2020.553576","article-title":"Immune (cell) derived exosome mimetics (IDEM) as a treatment for ovarian cancer","volume":"8","author":"Pisano","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2024092412010353400_bib11","doi-asserted-by":"crossref","first-page":"6917","DOI":"10.2147\/IJN.S264498","article-title":"Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications","volume":"15","author":"Zhang","year":"2020","journal-title":"Int J Nanomed"},{"issue":"1","key":"2024092412010353400_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"key":"2024092412010353400_bib13","doi-asserted-by":"crossref","first-page":"215949","DOI":"10.1016\/j.canlet.2022.215949","article-title":"BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"553","author":"Yang","year":"2023","journal-title":"Cancer Lett"},{"issue":"4","key":"2024092412010353400_bib14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1109\/TNB.2021.3097909","article-title":"Modeling of anti-cancer drug release kinetics from liposomes and micelles: a review","volume":"20","author":"Sawaftah","year":"2021","journal-title":"IEEE Trans NanoBioscience"},{"issue":"8","key":"2024092412010353400_bib15","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.exphem.2009.04.004","article-title":"Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets","volume":"37","author":"Giuliani","year":"2009","journal-title":"Exp Hematol"},{"issue":"12","key":"2024092412010353400_bib16","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood-2014-05-578732","article-title":"The Tao of myeloma","volume":"124","author":"Boise","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2024092412010353400_bib17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5694\/mja2.50129","article-title":"Biology and therapy of multiple myeloma","volume":"210","author":"Joshua","year":"2019","journal-title":"Med J Aust"},{"issue":"31","key":"2024092412010353400_bib18","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/JCO.2006.06.1853","article-title":"Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer","volume":"24","author":"Fanucchi","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024092412010353400_bib19","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/annonc\/mdj131","article-title":"Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits","volume":"17","author":"Yang","year":"2006","journal-title":"Ann Oncol"},{"issue":"8","key":"2024092412010353400_bib20","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024092412010353400_bib21","doi-asserted-by":"crossref","first-page":"e2103895","DOI":"10.1002\/advs.202103895","article-title":"Bortezomib-encapsulated dual responsive copolymeric nanoparticles for gallbladder cancer targeted therapy","volume":"9","author":"Chen","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"2024092412010353400_bib22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.actbio.2018.09.022","article-title":"Hyaluronic acid shell and disulfide-crosslinked core micelles for in\u00a0vivo targeted delivery of bortezomib for the treatment of multiple myeloma","volume":"80","author":"Gu","year":"2018","journal-title":"Acta Biomater"},{"issue":"9","key":"2024092412010353400_bib23","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14740338.2018.1513487","article-title":"The safety of bortezomib for the treatment of multiple myeloma","volume":"17","author":"Cengiz Seval","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"2024092412010353400_bib24","doi-asserted-by":"crossref","first-page":"113519","DOI":"10.1016\/j.expneurol.2020.113519","article-title":"Vincristine- and bortezomib-induced neuropathies - from bedside to bench and back","volume":"336","author":"Geisler","year":"2021","journal-title":"Exp Neurol"},{"key":"2024092412010353400_bib25","doi-asserted-by":"crossref","first-page":"9355","DOI":"10.2147\/IJN.S281890","article-title":"Advances in exosome-based drug delivery and tumor targeting: from tissue distribution to intracellular fate","volume":"15","author":"Shao","year":"2020","journal-title":"Int J Nanomed"},{"issue":"6478","key":"2024092412010353400_bib26","doi-asserted-by":"crossref","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"issue":"3","key":"2024092412010353400_bib27","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1039\/D0NR07622H","article-title":"Exosome-mediated delivery of gene vectors for gene therapy","volume":"13","author":"Duan","year":"2021","journal-title":"Nanoscale"},{"issue":"10","key":"2024092412010353400_bib28","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/cells12101416","article-title":"Current strategies for exosome cargo loading and targeting delivery","volume":"12","author":"Zeng","year":"2023","journal-title":"Cells"},{"issue":"1","key":"2024092412010353400_bib29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10787-022-01115-7","article-title":"Exosome engineering in cell therapy and drug delivery","volume":"31","author":"Sadeghi","year":"2023","journal-title":"Inflammopharmacology"},{"issue":"4","key":"2024092412010353400_bib30","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"2024092412010353400_bib31","doi-asserted-by":"crossref","first-page":"e0170628","DOI":"10.1371\/journal.pone.0170628","article-title":"A\u00a0comparative study of serum exosome isolation using differential ultracentrifugation and three commercial reagents","volume":"12","author":"Helwa","year":"2017","journal-title":"PLoS One"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4886\/2243829\/blooda_adv-2023-012464-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4886\/2243829\/blooda_adv-2023-012464-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T13:36:47Z","timestamp":1727185007000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/18\/4886\/516519\/Anti-BCMA-engineered-exosomes-for-bortezomib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":31,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,9,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012464","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]}}}